Platform Overview

Beactica’s proprietary and SPR-based small molecule drug discovery platform enables more efficient lead identification and optimization by giving a unique understanding of how compounds interact with its target protein. Beactica identifies and optimizes selective lead compounds with a high development potential and a reduced risk of failure in both early and late stages of the drug discovery process.

Key benefits include:

  • Wide range of targets amenable (structural determination not necessary)
  • High-quality interaction data for confident decisions (kinetics and selectivity)
  • Unique structural interpretation of interaction data
  • Very low protein consumption

Beactica's fragment-based approach works also when protein crystallisation is not possible. This means we can support you on a wider range of protein targets.